Sanofi/GSK restart COVID-19 vaccine trials after tweaking formulation
pharmaphorum
FEBRUARY 22, 2021
The vaccine is based around an adjuvanted recombinant protein, which will be tested in a new phase 2 study to assess the response including in older adults. Sanofi’s shot combines the recombinant DNA technology it uses to make flue vaccines with the adjuvants GSK uses to boost the immune system with its jabs.
Let's personalize your content